Laidlaw Capital Markets is Lead Manager in aTyr Pharma’s (LIFE) $86,250,000. Offering.
Laidlaw Capital Markets is pleased to have Lead Managed aTyr Pharma's (LIFE) $86,250,000. Offering alongside Piper Sandler and RBC. Read Article: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-pricing-75-million-public-offering-common
Laidlaw & Company enhances their Wealth Management offering with Envestnet | MoneyGuide
Laidlaw & Company enhances their Wealth Management offering with Envestnet | MoneyGuide NEW YORK, NY, UNITED STATES, March 11, 2020 /EINPresswire.com/ -- Laidlaw Wealth Management is pleased to announce it has chosen Envestnet, a Read More...
How artificial intelligence can control disease outbreaks
Watch Ann Marie Sastry's interview on CNBC's “Squawk Alley”. The CEO of AMESITE talks about her company and how artificial intelligence can be used in disease outbreaks and even to track the coronavirus. WATCH Read More...
Laidlaw served as Co-Manager on the $21.75mm EyePoint Pharmaceuticals (EYPT) Follow-On Offering.
Laidlaw Capital Markets is pleased to announce today's pricing of a $21,750,000 Follow-On Offering for EyePoint Pharmaceuticals (EYPT). Laidlaw proudly served as Co-Manager alongside Guggenheim, who was Sole Book-Runner on the transaction. See full Press Read More...
Laidlaw Venture Partners’ portfolio company Amesite CEO, Dr. Ann Marie Sastry, back on CNBC’s Squawk Box.
Ann Marie Sastry, founder and CEO of Amesite, joins “Squawk Box” to discuss how the Covid-19 pandemic is changing remote learnings for students and workers looking to continue their education.”
Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeff Conroy and George Serafin to its Board of Advisors. As industry leaders in Business Development and Regulatory/Compliance...
Stay In Touch